Zantac (Ranitidine)

Legal Claims for Prescription and Over the Counter Zantac and Ranitidine Users

Prescription and over-the-counter Zantac (Ranitidine) products approved by the United States Food and Drug administration (FDA) are suspected of causing various forms of cancer.

Goldberg & Osborne attorneys have experience representing injured patients against large multinational pharmaceutical companies. We are investigating potential claims on behalf of people and their loved ones who may have been injured by prescription and or over-the-counter Zantac (Ranitidine) use.

Call Goldberg & Osborne at 1-800-THE-EAGLE (1-800-843-3245)

or

submit an inquiry via email

Zantac is an H2 receptor antagonist (H2 Blocker) that treats heartburn, acid indigestion, ulcers, Gerd, and similar conditions by reducing the amount of acid produced in the stomach.

The FDA approval prescription Zantac for public use in June of 1983. After only five years on the market it was already the bestselling drug in the world, bringing one billion in annual sales. Prescription Zantac was the most prescribed drug in the United States for most of the early 1990s.

The FDA approved lower-strength version of Zantac for over-the-counter sale in 1995.

The generic form of Zantac known as Ranitidine was approved by the FDA in 1997.

In 2018 the Ranitidine manufacturer, Sanofi reported it made 113 million euros, the equivalent of roughly 124 million US dollars.

According to Bloomberg intelligence, nearly 25 million prescriptions for Ranitidine were written in 2018 alone.

In December of 2019, the FDA published a recall on Ranitidine tablets due to the possible presence of Nitrosodimethylamine (NDMA) impurities.

Exposure to Zantac (Ranitidine) has been linked to several cancers including but not limited to:

  • Breast Cancer
  • Bladder cancer
  • Kidney (renal) cancer
  • Pancreatic cancer
  • Prostate cancer
  • Esophageal/Throat/Nasal cancer
  • Lung cancer
  • Stomach cancer
  • Testicular cancer
  • Colorectal cancer
  • Liver cancer
  • Brain Cancer
  • Uterine Cancer
  • Thyroid Cancer
  • Ovarian Cancer

Some of the common Zantac and Ranitidine names are:

  • Zantac 150 Tablets
  • Zantac 150 Maximum Strength
  • Zantac 150 Maximum Strength Cool Mint
  • Zantac 750 Tablets
  • Wal-Zan 150
  • Wal-Zan 75
  • Heartburn Relief (Ranitidine)
  • Acid Reducer (Ranitidine)
  • Acid Control (Ranitidine)

Sources:

U.S Food and Drug Association, Drugs@FDA: FDA-Approved Drugs, June 9, 1983, (Source)

U.S. Food and Drug Association, Drugs@FDA: FDA-Approved Drugs, December 19, 1995, (Source)

U.S. Food & Drug Association, Drugs@FDA: FDA-Approved Drugs, November 18, 1997, (Source)

Sanofi, Form 20-F, 2018 (Source)

Bloomberg, Carcinogen in Zantac and Generics Triggers FDA, EU Probes, September 13, 2019, (Source)

U.S. Food & Drug Association, Glenmark Pharmaceuticals Inc., USA Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity, December 17, 2019 (Source)

U.S. Food & Drug Association, FDA Requests Removal of All Ranitidine Products (Zantac) from the Market, April 01, 2020 (Source)


Let Us Help You Seek Justice

Email us information about your potential claim, or give us a call 24/7 at 1-800-THE-EAGLE (1-800-843-3245) for a free, no obligation consultation.
  • I agree that I am not a client of Goldberg & Osborne for this matter unless I sign a written fee agreement with the Firm.

  • This field is for validation purposes and should be left unchanged.